#CD3Engager
Featured today by @MSKLibrary: Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific dx.doi.org/10.1016/j.xc...

#CancerImmunotherapy #TumorMicroenvironment
#ImmunoOncology #TCellTherapy #Tebentafusp #CD3Engager #ImmuneLandscape #Cancer
April 23, 2025 at 4:34 PM